Classes
DEA Class; Rx
Common Brand Names; Viread
- HIV, NRTIs
Description
Nucleotide reverse transcriptase inhibitor
Used for the treatment of HIV infection and chronic HBV infection
Decreases in bone mineral density reported in patients receiving tenofovir
Also available combined with emtricitabine (Truvada), emtricitabine/efavirenz (Atripla), emtricitabine/rilpivirine (Complera)
Indications
Indicated in combination with other antiretroviral agents for treatment of HIV-1 infection
Indicated for chronic hepatitis B
Adverse Effects
- Asthenia (11%)
- Diarrhea (16%)
- Nausea (11%)
- Pain (12%)
- Anorexia
- Depression
- Myalgia
- Peripheral neuropathy
- Dyspepsia
- Rash
- Headache
- Vomiting
- Flatulence
- Abdominal pain
- Neutropenia
Warnings
May cause redistribution/accumulation of body fat that may result in cushingoid appearance
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including TDF, alone or in combination with other antiretrovirals; treatment should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in absence of marked transaminase elevations)
Pregnancy and Lactation
Not recommended for use during pregnancy; substantially lower exposures of cobicistat and elvitegravir reported during second and third trimesters
The Centers for Disease Control and Prevention do not recommend HIV-infected mothers breastfeed their infants due to potential risk for postnatal transmission of HIV
Maximum Dosage
300 mg/day PO.
300 mg/day PO.
8 mg/kg/day PO (Max: 300 mg/day).
2 to 12 years weighing 17 kg or more: 8 mg/kg/day PO (Max: 300 mg/day).
2 to 12 years weighing 10 to 16 kg: 8 mg/kg/day PO for the powder; safety and efficacy of the tablets have not been established.
2 to 12 years weighing less than 10 kg: Safety and efficacy have not been established.
1 year: Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Tenofovir disoproxil fumarate (ie, tenofovir DF)
tablet
- 150mg
- 200mg
- 250mg
- 300mg
powder, oral
- 40mg/g of powder (ie, 1 scoopful)
